Other trials are recruiting to test the efficacy of Atezolizumab as adjuvant for first line therapies in patients with metastatic HER2-positive breast cancer (NCT03125928, NCT03199885, NCT03417544) or in combination with other drugs, with Trastuzumab + Vinorelbine (NCT04759248), with doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) (NCT03726879), or with a HER2/4-1BB bispecific antibody (NCT03650348). The gene discussed is ERBB2; the disease is breast carcinoma.